Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb trial of recombinant COVID-19 vaccine (Sf9 cells) in adults and older adults
ChiCTR2100042374Phase 2Recruiting
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Incidence of adverse reactions within 0 to 7 days after each immunization and Incidence of adverse events of special interest from first immunization to 60 days after last immunization. Started Jan 2021; status: recruiting.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100042374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042374.